Despite optimal medical treatment and strict low-protein diet, the prognosis of propionic acidemia (PA) patients is generally poor. We aim to report our experience with liver transplantation (LT) in the management of PA patients. Six patients with PA received a LT at a mean age of 5.2 years (1.3-7.5 years). The indications for LT were frequent metabolic decompensations in the first 4 patients and preventative in the last 2 patients. Two patients presented hepatic artery thromboses that were solved through an interventional radiologist approach. These patients showed a very high procoagulant state that was observed by thromboelastography. Arterial vasospasm without thrombus was observed in 2 patients during the LT surgery. In order to avoid hepatic artery thrombosis, an arterial conduit from the recipient aorta to the hepatic artery of the donor was used in the fifth patient. After LT, patients presented improvement in propionyl byproducts without complete normalization, but no decompensations have been observed. In conclusion, LT could be a good therapeutic option to improve the metabolic control and the quality of life of PA patients. Improved surgical strategies along with new techniques of interventional radiology allow us to perform the LT minimizing the complications derived from the higher risk of hepatic artery thrombosis.
Propionic acidemia (PA; Online Mendelian Inheritance in Man number 606054) is an autosomal-recessive inborn error of metabolism of branchedchain amino acids in which propionyl-coenzyme A carboxylase (PCC) activity is reduced. PCC is located in the mitochondrial matrix, and it is responsible for the conversion of propionyl-coenzyme A (CoA) into methylmalonyl-CoA that is subsequently transformed into succinyl-CoA, which enters the tricarboxylic acid cycle to generate nicotinamide adenine dinucleotide, the main substrate used by the mitochondrial respiratory chain. (1) PCC deficiency leads to an accumulation of propionyl-CoA and its byproducts, which are toxic mainly for the central nervous system and the heart. (2, 3) Despite following a strict dietary and medical treatment, patients can present metabolic decompensations that can result in severe cardiac and neurological sequelae (2) (3) (4) (5) with a 15-year survival rate of <50%. (6, 7) Moreover, the treatment complexity, the poor longterm neurological outcomes, and the frequent admissions finally cause a deficient quality of life for PA patients and their families. (8) The liver is the main site of action of the amino acid transamination, but PCC is also present in other organs besides the liver. Thereby, liver transplantation (LT) is not a completely curative treatment but provides partial correction of the metabolic deficiency decreasing the amount of toxic products. (9) Some studies have reported benefits of LT, such as minimizing the risk of metabolic decompensations and improving nutrition and quality of life of PA patients. (9, 10) However, results regarding cardiac evolution are variable, and some neurocognitive sequelae are possibly nonreversible. (11) Original article | 1737
Although LT is a highly expensive treatment, especially during the first posttransplant year, direct and indirect costs derived from lifetime maintenance on nutritional support in PA patients could be higher. (12) On the other hand, the reported rates of hepatic arterial thrombosis (HAT) and posttransplant renal dysfunction are higher than in other LT indications. (11) These facts together with the adverse effects derived from immunosuppression have led some pediatric metabolic teams to not refer their patients for LT evaluation.
Because of the long experience and positive results with LT in our group and the expertise on metabolic diseases of Hospital Vall d'Hebron and Hospital Sant Joan de Déu, we decided to consistently propose LT as a treatment for PA patients since January 2012. The aim of this study was to evaluate the role of LT as a treatment of options for PA patients regarding aspects of their complications and management.
Patients and Methods
PA patients from Metabolic Units of Hospital Vall d'Hebron and Hospital Sant Joan de Déu were referred to the Pediatric Liver Transplant Unit of Hospital Vall d'Hebron to be evaluated as LT candidates. PA patients who finally received a LT were included in the study. The diagnosis of PA was made by a mutation analysis and low PCC activity in cultured fibroblasts in all patients.
Patient data were obtained by reviewing inpatient and outpatient medical records and our prospective transplant database. Demographic, clinical, and laboratory data were recorded. We also gathered the indication for LT, pre-LT evaluation (cardiac, neurological, and kidney function), pre-and post-LT medical and dietary treatment, pre-and post-LT number of decompensations and hospital admissions, post-LT complications, and longterm follow-up (cardiac, renal, and neurological evolution and mortality). 
inDicatiOn FOr lt in pa patients
Initially, PA patients were eligible for LT if they presented multiple metabolic decompensations despite properly following the dietary and medical treatment prescribed and if no serious neurological alterations were observed in the pre-LT neurological assessment. Because of the good results observed in the first 4 patients, the indication for LT was also opened to stable patients not suffering metabolic decompensations and without severe pre-LT neurological sequelae.
pre-lt evaluatiOn
Besides the conventional pre-LT studies, PA patients were specially referred to a pediatric cardiologist and nephrologist. Echocardiography and arrhythmia studies along with a detailed study of renal function were performed on these patients. Also, a neurological assessment was performed to evaluate pretransplant status using the Griffiths Mental Development Scale score.
The Griffiths Mental Development Scales are widely used by pediatricians and psychologists to measure the rate of development of infants and young children from birth to 8 years of age, and they have been previously used to assess the neurological evolution of PA patients. (9) The 6 areas of development measured by the scales are locomotor, personal-social, hearing and language, eye and hand coordination, performance, and practical reasoning (normal range, 80-120 for each parameter). (13) Furthermore, LT was scheduled after taking into account the number of metabolic decomposations that would be required and also after reaching an agreement with the metabolic team.
MetaBOlic cOntrOl During surgerY
metabolic monitoring was done using central venous pH, lactates, and arterial ammonia.
iMMunOsuppressiOn
All patients followed immunosuppression according to our standard protocol. (14) Induction therapy consisted of 10 mg/kg of methylprednisolone intravenously before hepatic revascularization, followed by 2.5 mg/kg twice daily, and then tapering to 1 mg/kg/day over 6 days. Basiliximab was administered intravenously on the 1st and 5th postoperative days at 10 or 20 mg depending on the patient's weight (>30 or ≤30 kg, respectively). Tacrolimus at a dose of 0.075 mg/kg twice daily was started in the pediatric intensive care unit (PICU) via a nasogastric tube until oral intake was tolerated to achieve a trough level of 8-12 ng/mL during the first 2 weeks. Subsequently, patients followed the standard protocol of longterm immunosuppression consisting of low-dose corticoids combined with tacrolimus to reach trough levels between 3 and 5 ng/dL at 1 year after LT.
lt FOllOW-up
To monitor graft function, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase, gamma-glutamyltransferase, and serum lactate were measured twice daily for the first 5 postoperative days. Subsequently, they were measured daily during 10 days, weekly during 1 month, every other week during 2 months, monthly until 6 months, and every 2-3 months thereafter.
To assess arterial and portal vein patency, Doppler ultrasound (DUS) was performed every morning for the first 5 postoperative days or whenever vascular thrombosis was suspected. Subsequently, DUS was performed weekly for 1 month, every other week for 2 months, monthly until 6 months, and every 2-3 months thereafter.
anticOagulatiOn

MOnitOring anD prOpHYlaXis
Anticoagulation monitoring was done according to our standard protocol. Antithrombin III (AT-III) activity was measured once a day for the first 5 days after LT. International normalized ratio (INR), prothrombin time, activated partial thromboplastin time, fibrinogen, and platelets were measured twice daily for the first 5 days after LT. Subsequently, they were measured daily for 1 week, weekly for 1 month, and every 2-3 months thereafter.
Anticoagulation consisted of low-molecular-weight heparin, AT-III, and dipyridamole. Low-molecularweight heparin was started at 1 mg/kg/day subcutaneously once daily when in 2 consecutive blood tests, platelet count was >50,000 × 10 9 /L, INR <2, activated partial thromboplastin time was <100 seconds, and no active bleeding was detected. AT-III concentrates were administered if its activity was under 60%. The AT-III dose was obtained following this equation: international units (IU) of AT-III = (100 -AT-III activity) × patient weight. Dipyridamole was started at a dose of 1 mg/kg 3 times daily when the platelet count was 80,000 × 10 9 /L. Low-molecular-weight heparin was continued for 2 weeks. Dipyridamole was replaced by acetylsalicylic acid 1 week after LT continuing for 3 months following LT. (15) 
MetaBOlic FOllOW-up
The assessment of propionate metabolites in urine (propyonil glycine, methylcitrate, tiglylglycine, and 3 OH-propionate) was made by gas chromatographymass spectrometry at hospital admission; at 1, 7, and 30 days after LT; and every 2-3 months thereafter. Acute metabolic decompensations were defined as ketoacidosis with hyperammonemia requiring emergency treatment and hospitalization.
After the transplant, patients increased progressively the protein intake in order to achieve the daily food recommendations by their age but not a normal unrestricted diet. If a patient presented elevation of propionate metabolites reaching levels close to their pre-LT baseline situation, protein intake increase was stopped until the restoration of basal metabolites levels. Carnitine was continued in normal doses (100 mg/ kg/day).
assessMent OF eXtraHepatic DaMages
Renal function was evaluated by serum creatinine and estimated glomerular filtration rate (eGFR) using the Schwartz modified formula. (16) Echocardiography was performed during the pre-LT evaluation and every year during post-LT follow-up. The neurological evolution was assessed using the Griffiths Mental Development Scales score before LT and 1 year after LT.
Results
Between January 2012 and December 2016, 62 pediatric LTs were performed in our center, and the patient and graft survival rates were the same-97.6% (data obtained by the hospital registry). During that period, 6 PA patients with a median of 5.2 years of age (1.3-7.5 years) underwent transplantation in our institution. Five of them were diagnosed before 3 months of age. The median time on the waiting list was 6.3 months (4.8-7.1 months).
sYMptOMs at Disease Onset
Four patients presented metabolic acidosis with hyperammonemia and intoxication symptoms such as coma, lethargy, or hypotonia before 3 months of age (patients 1-4). Patient 5 was diagnosed with the newborn screening, and treatment was started before symptom development. The remaining patient (patient 6) presented a metabolic decompensation at 3 years of age, having a mild neurodevelopmental delay at disease onset. Except for patient 5, all patients were successfully managed with hemodiafiltration, L-carnitine, and low protein intake at disease onset. None of the patients had positive family history, and only patient 1 was consanguineous.
sYMptOMs OF pa BeFOre lt
Two patients presented seizures during their evolution that responded to treatment with levetirazetam (patients 3 and 4). Four patients (patients 1-4) needed feeding support using a nasogastric tube or gastrostomy. All patients followed a strict diet with a very low protein intake (median of total protein intake of 0.7 mg/kg/ day; 0.6-0.8 mg/kg/day) and L-carnitine (Table 1) .
inDicatiOn FOr lt
Frequent decompensations were the main cause for LT in 4 patients (patients 1-4; Table 2 ). Patient 5 presented mild developmental delay with no metabolic decompensations. Patient 6 was diagnosed at 3 years of age in the setting of a metabolic decompensation. At disease onset, the patient presented a mild neurodevelopment delay and treatment with a low-protein diet, carnitine, and metronidazole was started. Subsequently, no other episodes of metabolic decompensation were observed and the indication for LT was also preventative. In these 2 patients, parental choice endorsed by doctors was to perform the LT as a preemptive treatment, given the good results in pediatric LT of our team. Details regarding pre-LT characteristics are summarized in Table 1 .
liver transplantatiOn
The surgical technique used was previously described by our group. (17) Three patients received a whole liver graft, and the other 3 received a partial graft from a living donor liver transplantation (LDLT). In patient 3, a life-threatening arrhythmia with hemodynamic instability was observed during hepatectomy. The patient was scheduled to undergo a transplant using a living donor, so after her stabilization, the procedure was stopped and the donor was not operated on. Because the arrhythmia could be related to a not well-studied pre-LT cardiac lesion, another cardiac assessment was done, including a new echocardiography and a complete arrhythmia study with normal results. One month later, the patient received a whole liver graft without any complication either during the surgery or in the follow-up (Table 2) .
Vascular Complications
HAT occurred in 2 patients (patients 1 and 6). In patient 1, HAT was detected 3 months after the LT in a control DUS with a normal liver function. It was successfully treated with a stent placement in the hepatic artery. In patient 6, despite performing a good arterial anastomosis, no flow was obtained intraoperatively. The biliary duct was exteriorized using a tube, and the patient was rapidly transferred to the interventional radiologist room in order to find out the reason for the lack of arterial flow. A vasospasm was diagnosed, and it was successfully reverted with the administration of intra-arterial vasodilators. A DUS performed in the PICU 36 hours after the procedure revealed an absence of arterial flow, and the patient underwent a new radiology study. In the arteriography, HAT was present without stenosis of the arterial anastomosis being successfully treated with a fibrinolytics. Nevertheless, a stent was required to maintain the hepatic artery patency. 
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In patient 4, despite performing a good arterial anastomosis, no flow was achieved intraoperatively. The biliary duct was exteriorized by a tube, and the patient was transferred to the interventional radiologist room. Vasospasm was diagnosed without thrombosis, and it was successfully reverted with the administration of intra-arterial vasodilators. At the end of follow-up of this study, patency of hepatic artery was still present in patient 4.
In order to avoid vascular complications observed in these patients, arterial anastomosis in the last 2 patients were planned to be done using a conduit directly from the recipient aorta to the hepatic artery of the donor. Unfortunately, it was not possible to carry out this technique in patient 6 due to a mismatch in size between the donor artery and the conduit, and finally, a termino-terminal hepatic artery anastomosis was done.
Biliary Complications
In 2 patients (patients 4 and 6), biliary anastomosis was delayed due to restoration of the arterial blood flows in the interventional radiologist room. Enterobiliary anastomosis was performed 2 and 7 days after the LT, respectively.
No other biliary complications were observed during the follow-up in the HAT patients.
There was no clinical or biochemical evidence of postoperative decompensations in patients with vascular complications.
lt cOagulatiOn MOnitOring
Initially, the conventional anticoagulant protocol used by our group was applied in all patients. Despite INR, activated partial thromboplastin time, AT-III, and platelet count seemed to reveal an anticoagulation situation during the LT in patients 1, 3, and 6, and therefore, a thromboelastography was performed. All 3 patients presented a procoagulant situation with an extremely short time of reaction and clotting time, with a high alpha angle showing hyperaggregability and elevated fibrinogen formation. In patients 4 and 6, despite performing a good arterial anastomosis, the lack of arterial flow persisted and a continuous intravenous heparin infusion was administered.
MetaBOlic cOntrOl During lt
The metabolic profile performed during the LT in the last 2 patients revealed a general intraoperative catabolic activation with elevation of lactate and increased ketonuria as is usually seen during LT. Primary metabolites such as 3-OH-propionate and propionyl glycine presented highly elevated levels, especially during the anhepatic phase, that decreased importantly afterward. Secondary metabolite levels (methylcitrate and tiglylglycine) remained stable until the anhepatic phase. After that, urine concentration declined except for methyl citrate, which is usually more stable (Fig. 1) .
pOst-lt evOlutiOn
The median PICU and hospital stay were 6.5 and 15.0 days (4-11 and 9-22 days, respectively). Two patients presented a mild decrease in the eGFR compared with the pre-LT period (patients 1 and 4), although no patient presented severe kidney dysfunction at the end of the follow-up. No alteration at 1 year after LT echocardiography was observed in any patient. Patients using pre-LT nutritional support (nasogastric tube or gastrostomy) were free of any support at a median of 3 months after the LT (0.5-6.3 months). At the end of follow-up, all children were alive, and no retransplant was required ( Table 2 ).
All patients followed the standard protocol of longterm immunosuppression consisting of low-dose corticoids combined with tacrolimus to reach trough levels between 3 and 5 ng/dL. No episodes of acute rejection proved by biopsy were observed during the follow-up.
MetaBOlic evOlutiOn aFter lt
After a median follow-up of 1.6 years (0.2-3.7 years), no decompensations were observed. The primary and secondary metabolites presented an important decrease after LT. However, these toxic metabolites were not completely normal, thus supporting the need of continuing with protein restriction (Fig. 2) . Moreover, this metabolic profile improvement was achieved with a significant increase in protein intake 1 year after the LT (from 0.7 [range, 0.5-0.8] mg/kg/day before LT to 1.3 [range, 1-1.5] mg/kg/day at 1 year after LT). All patients continued carnitine treatment. In patients 4 and 6, protein intake increase was temporarily stopped at 0.7 and 0.6 mg/kg/day because the patients presented elevation of propionate metabolites reaching similar levels to their pre-LT baseline situation. One month later, propionate metabolites declined, and the intake was increased to 0.9 and 0.8 mg/kg/day, respectively.
neurOlOgical HealtH anD QualitY OF liFe aFter lt
Prior to LT, all patients presented some degree of neurodevelopmental delay. One year after LT, stabilization 
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and even improvement in the neurological impairment were observed in all patients (Table 2) . Although we did not perform a systematic assessment of the quality of life in patients and their families, it seemed to be better than in the pre-LT period considering the better neurological evolution, the lack of metabolic decompensations, and the easier-to-follow diet. The 2 patients presenting seizures at diagnosis had controlled the epilepsy using monotherapy with levetirazepam.
Discussion
To our knowledge, this is one of the largest series of LT PA patients. PA is a severe inborn error of metabolism in which patients are at a high risk of metabolic decompensations despite following a strict medical and dietary treatment. Chronic toxic metabolite accumulation usually results in mental retardation and deterioration of quality of life. (4) Because LT offers excellent outcomes in children with survival rates higher than 85% in experienced centers, (18) it is increasingly used as a treatment for inborn errors of metabolism. (19) Experience in LT for organic acidemia is not very large and results of previous series are very variable, showing a wide range of potential peri-and post-LT complications. (11) Although in our population only 2 patients presented very early onset disease, which is known to be related to worse outcomes, the results in terms of survival, neurological evolution, and quality of life were very satisfactory. Some previous articles have reported poor outcomes, with both a 5-year graft survival rate of 60% and also a number of unexpected complications in the short-term and longterm follow-up. (11) Differences observed with previous cohorts may be explained by the different surgical techniques, immunosuppression used in the 1990s, and probably patient selection. On the other hand, more recent series also show very good results in terms of metabolic control and survival. (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) Regarding HAT, the reported rates in transplanted PA patients are higher than in other indications for LT. (9) (10) (11) In our experience, when the inherent predisposition to HAT is joined with complex vascular reconstruction, as is usually seen in LDLT, the rate of thrombosis is much higher. (11) The overall incidence of HAT in our institution in the last 10 years is 5.9%, including LT in PA patients. Moreover, in the 2 HAT patients in our series, no anastomotic stenosis or technical complications were observed in the angiography.
Although standard coagulation tests were usually normal during the surgical period, patients showed a very high procoagulant state, observed by thromboelastography. Additionally, the use of thromboelastography on the coagulation monitoring rather than conventional coagulation tests could be useful.
In addition, it seems that in PA patients who undergo LT, the consistence of the arterial wall is lower than normal. Thus, the educated impression is that the first event observed is a collapse of the hepatic artery followed by the thrombus production. Taking these facts into account, when the absence of arterial flow was observed during the surgical procedure, the patient was directly transferred to the interventional radiology room. Because of this rapid transfer, an arterial vasospasm was observed in patients 4 and 6 without any thrombus. This vascular complication had not previously been described in PA patients. In Alagille syndrome, another indication for LT related to higher rates of HAT, the use of an arterial conduit from the aorta has been proposed as an alternative. (21) In patient 5, to avoid HAT, an arterial conduit from the recipient aorta to the hepatic artery of the donor was directly used without any complications after the surgery. Given the high rate of HAT observed in our cohort, we planned to use arterial conduits directly from the recipient aorta in LTs in PA patients.
Auxiliary LT has been successfully used as an alternative to whole LT in some noncirrhotic inborn errors of metabolism such as Crigler-Najjar or urea cycle disorders. (22, 23) The main advantage of this technique is that if the donor graft fails, it can be removed leaving the native liver as a backup. Moreover, it leaves open the possibility of performing gene therapy in the future. There are also some case reports showing good outcome using this technique in PA patients. (24) Nowadays, the possibility to apply auxiliary LT to treat noncirrhotic inborn errors of metabolism base in the liver is being evaluated in our center.
Some complications may appear in the longterm follow-up, especially cardiomyopathy and kidney dysfunction. (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) Regarding renal failure, it is well described that patients with methylmalonic acidemia (another organic acidemia that shares some metabolic pathways with PA) presented kidney dysfunction after LT, especially related to the renal elimination of some metabolites and the use of tacrolimus. (4) Moreover, it is possible that when using low-protein diets, the eGFR was overestimated. So when protein intake was liberalized, renal dysfunction became apparent. Two patients presented mild kidney dysfunction after LT (patients 1 and 4). Although the series is too short to make definitive conclusions, taking into account previous reports and the experience in LT for other indications, it makes sense to consider that this kidney dysfunction could be intrinsic to PA instead of related only to anticalcineurinic treatment.
In our series, no patient presented cardiac manifestations prior to the transplant. Moreover, no alterations were observed in the annual echocardiography. Other complications such as multiorgan failure in the early post-LT period were not observed in our series. Unexplained cardiac failure in transplanted PA patients has been reported, possibly related to undetected pre-LT cardiac dysfunction. In patient 4, a life-threatening arrhythmia was observed during the surgery. It has been described that PA patients (even in clinically stable situations) can present disturbances in cardiac electrophysiology such as prolongation of the QT interval that can contribute to cardiac complications. Possible mechanisms include effects of toxic metabolites or deprivation of essential substrates. (5) Although our patient was in a very stable pre-LT situation, the arrhythmia could be related to a not well-studied pre-LT cardiac lesion. After a new echocardiogram and a complete arrhythmia study that showed normal results, the patient was successfully transplanted and no cardiac complications were observed either during the surgery or during follow-up.
In other previous series, no protein restriction diet was prescribed. (9) Because LT does not completely replace enzyme activity, some extrahepatic propionyl metabolites are likely to be produced, (10) which could explain why we observed an improvement in these propionyl byproducts but not complete normalization. Moreover, some reports highlight that patients with methylmalonic acidemia who received a liver transplant presented an increase of toxic metabolites in the cerebrospinal fluid and a neurological deterioration after a liberalized protein intake. (25) Current dietary and medical treatment does not seem to effectively prevent neurological deterioration, and pathophysiological mechanisms are poorly understood. Some articles have shown evidence for the expression of PCC and methylmalonyl-CoA mutase in rats' neurons. (26) Considering these results, our protocol was to increase proteins until achieving daily food recommendations and maintaining carnitine treatment in order to ensure the proper metabolite urine elimination. With this strategy, we provided an adequate supply of proteins but used a clearly lower protein intake than conventional protein unrestricted diets.
Neurodevelopmental delay is one of the most severe problems in PA patients. (2) In our experience, LT is useful not only for avoiding the metabolic decompensations but also in stabilizing the neurological impairment and in some cases improving the basal state. The excellent evolution of our patients in terms of neurological outcome after LT would be partially explained because some of them are patients with nonsevere forms with good metabolic control and shorter and less severe pre-LT metabolic intoxication. As the neurological improvement is very much possible in younger nonsevere patients, a possible indication for LT would be young PA patients without or with very low neurological delay.
However, the results obtained should be considered in light of the limitations of the study (relatively shortterm follow-up and single-center retrospective study with few patients).
In conclusion, LT could be a very good therapeutic option to improve the metabolic control and the quality of life of PA patients despite posttransplant morbidity. Good surgical strategies along with the new techniques of interventional radiology allow us to perform the LT minimizing the complications derived from the higher risk of HAT. A complete pre-LT cardiac evaluation should be performed, including echocardiography and arrhythmia assessment to avoid unexpected cardiac complications.
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